At the 2018 AIBD Meeting, Dr William Sandborn discusses the biologics and positioning of anti-interleukin-12 and anti-interleukin-23 agents for inflammatory bowel disease.
In a Keynote session at the 2018 AIBD Meeting, Dr Eugene Chang discusses the importance of understanding the gut microbiome, genetic pathways in microbes, and its impact on IBD.
Dr Gary Lichtenstein and colleagues evaluated whether age is a risk factor for adverse events from tofacitinib therapy for the treatment of ulcerative colitis.
